Peer review reports
From: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
Original Submission |
5 Jun 2022 |
Submitted |
Original manuscript
|
Resubmission - Version 2 |
|
Submitted |
Manuscript version 2
|
Resubmission - Version 3 |
|
Submitted |
Manuscript version 3
|
Resubmission - Version 4 |
|
Submitted |
Manuscript version 4
|
5 Oct 2022 |
Reviewed |
Reviewer Report
|
8 Oct 2022 |
Reviewed |
Reviewer Report - Ilhami Yüksel
|
1 Nov 2022 |
Author responded |
Author comments - Guillaume Bouguen
|
Resubmission - Version 5 |
1 Nov 2022 |
Submitted |
Manuscript version 5
|
15 Nov 2022 |
Reviewed |
Reviewer Report
|
Resubmission - Version 6 |
|
Submitted |
Manuscript version 6
|
Publishing |
15 Nov 2022 |
Editorially accepted |
|
1 Dec 2022 |
Article published |
10.1186/s12876-022-02583-5
|
Learn about peer review